These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32100259)

  • 21. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
    Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
    Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
    Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
    Ahn DH; Uson Junior PLS; Masci P; Kosiorek H; Halfdanarson TR; Mody K; Babiker H; DeLeon T; Sonbol MB; Gores G; Smoot R; Bekaii-Saab T; Mahipal A; Mansfield A; Tran NH; Hubbard JM; Borad MJ
    Invest New Drugs; 2022 Feb; 40(1):134-141. PubMed ID: 34463891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
    Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
    Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
    Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
    Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
    Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
    Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
    Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Yokoyama M; Ohnishi H; Ohtsuka K; Matsushima S; Ohkura Y; Furuse J; Watanabe T; Mori T; Sugiyama M
    Jpn Clin Med; 2016; 7():33-39. PubMed ID: 28008299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.
    Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
    Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
    Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 38. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
    Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
    J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision Medicine in Biliary Tract Cancer.
    Scott AJ; Sharman R; Shroff RT
    J Clin Oncol; 2022 Aug; 40(24):2716-2734. PubMed ID: 35839428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
    Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
    Front Oncol; 2022; 12():930611. PubMed ID: 36072793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.